


Name

- Shao-Chun Wang

Title

Professor & Co-Director,
Graduate Institute of Biomedical Sciences; Investigator &
Deputy Director, Center for Molecular Medicine
China Medical University and Hospital

**Contact**

- Office: Cancer Center Building 9F, China Medical University Hospital, 6 Hsueh-Shih Road, Taichung 404, Taiwan, R.O.C.
- Tel: +886-4+ 22052121 ext. 7923
- E-mail: wangsc@mail.cmuh.org.tw, scpwang@gmail.com

Resume

- Education and Training:
 - 07/1984-07/1988 B.Sc. - Pharmacy, Taipei College of Medicine, Taipei, Taiwan
 - 09/1988-07/1990 Military Service (Second Lieutenant of Air Force, Taiwan R.O.C.)
 - 09/1990-12/1995 Ph.D. - Genetics and Cell Biology, University of Minnesota Twin Cities, Minnesota, USA (Mentor: Dr. Peter Lefebvre)
- Experiences:
 - 01/1996-03/1998 Post-doctoral fellow - tumor biology, University of Texas M. D. Anderson Cancer Center, Houston, Texas USA (Mentor: Dr. Mien-Chie Hung)
 - 04/1998-05/2000 Research Associate - Molecular and Cellular Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas USA (Mentor: Dr. Mien-Chie Hung)
 - 05/2000-01/2002 Instructor, University of Texas M. D. Anderson Cancer Center, Department of Molecular and Cellular Oncology, Houston, Texas (Mentor: Dr. Mien-Chie Hung)
 - 02/2002-02/2007 Research-track Assistant Professor, University of Texas M. D. Anderson Cancer Center, Department of Molecular and Cellular Oncology, Houston, Texas

(Mentor: Dr. Mien-Chie Hung)

03/2007-08/2008 Assistant Professor, Department of Surgery, University of Cincinnati College of Medicine, Ohio

09/2008-08/2014 Assistant Professor, Department of Cancer Biology, University of Cincinnati College of Medicine, Ohio (formerly the Department of Cancer and Cell Biology)

2007-present Faculty, Cancer and Cell Biology Graduate Program, University of Cincinnati College of Medicine, Ohio

2007-present Associate Member, University of Cincinnati Cancer Center, Ohio

2011-present Member, Center for Clinical and Translational Science and Training (CCTST), University of Cincinnati, Ohio

2013-present Member, Cincinnati Cancer Center (CCC)

2013-present Member, University of Cincinnati Cancer Institute (UCCI)

09/2014-01/2016 Associate Professor, Department of Cancer Biology, University of Cincinnati College of Medicine, Ohio

01/2016-present Adjunct Associate Professor, Department of Cancer Biology, University of Cincinnati College of Medicine, Ohio

01/2016-present Full Research Fellow, Center of Molecular Medicine, China Medical University Hospital, Taichung, Taiwan

01/2016-present Deputy Director, Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan

03/2016-present Professor, School of Medicine, China Medical University, Taichung, Taiwan

08/2016-present Co-Director, Institute of Biomedical Sciences, China Medical University, Taiwan

● Honors and awards:

1996-1997 Breast Cancer Research Project Award, University of Texas, M. D. Anderson Cancer Center,

1999-2000 W. M. Keck Center for Cancer Gene Therapy Development Awards for the Human Cancer Gene Prevention and Therapy Program, University of Texas, M. D. Anderson Cancer Center,

2000-2002 Susan G. Komen Breast Cancer Foundation Translational Research Award (PI)

2003-2007 American Cancer Society Research Scholar Grant

	(RSG-03-138-01-CCD 01) (Co-PI)
2007-2008	University of Cincinnati Cancer Center Research Award
2008-2011	Susan Komen Investigator-Initiated Research Grant Award
2008-2012	Department of Defense (DOD) Prostate Cancer Research Program 2010-2011 Marlene Harris Ride Cincinnati Breast Cancer Research Award (PI)
2011-2012	University of Cincinnati Center for Clinical & Translational Science & Training (CCTST) Junior Investigator Pilot Grant (PI)
2012-2013	University of Cincinnati Provost's Pilot Research Award (PI)
2012-2014	Elsa U. Pardee Foundation Research Grant (PI)
2013	University of Cincinnati College of Medicine Internal Study Section Award for meritorious grant proposal
2013-present	NIH Early Career Reviewer (ECR) program of Center for Scientific Review (CSR)
2013-2015	American Heart Association (AHA) Research Grant (PI)
2015-2016	Marlene Harris Ride Cincinnati Breast Cancer Research Award (PI)

Fields of Specialty

- Signal Transduction
- Tumor Progression
- DNA Damage and Cell Proliferation
- Environmental Endocrine Disruptors

Research

- Use molecular, biochemical, cellular, and genetic experimental approaches to study biological mechanisms underlying normal and cancer cells to study cancer proliferation, metabolism, microenvironment, metastasis.
- To help solve unmet medical needs in cancer therapy such as drug resistance (of targeted therapies), metastasis. We focus on triple-negative breast cancer (TNBC) and are interested in other cancer types, as well as metabolic diseases such as obesity.

Paper & Project

1. De Toni, E.N., Ziesch, A., Rizzani, A., Török, H.-P., Hocke, S., Lü, S., **Wang, S.-C.**, Hucl, T., Göke, B., Bruns, C., Gallmeier, E. Inactivation of *BRCA2* in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis. *Oncotarget*, 7(8):9477-9490, 2016.
2. Broering, T.J., Wang, Y.-L., Pandey, R.N., Hegde, R.S., **Wang, S.-C.**, Namekawa, S.H. BAZ1B is dispensable for H2AX phosphorylation on Tyrosine 142 during spermatogenesis. *Biology Open*, 4(7):873-884, 2015.
3. Wang, Y.-L., Overstreet, AM, Chen, M.-S., Wang, J., Zhao, H., Ho, P.-C., Molly, S., **Wang, S.-C.** Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of *HOTAIR*. *Oncotarget* 6(13), 11150-11161, 2015.
4. Hsieh, T.-H., Hsu, C.-Y., Tsai, C.-F., Long, C.-Y., Chai, C.-Y., Hou, M.-F., Lee, J.-N., **Wang, S.-C.**, and Tsai, E.-M. miR-125a-5p is a prognostic biomarker that targets HDAC4 to suppress breast tumorigenesis. *Oncotarget* 6(1), 494-509, 2015.
5. **Wang, S.-C.** PCNA – a ubiquitous house keeper or a potential therapeutic target? *Trend in Pharmacological Sciences (TiPS)* 35, 178-186, 2014.
6. Zhao H., Chen, M.-S., Lo, Y.-H., Waltz, S.E., Wang, J., Ho, P.C., Vasiliasuskas, J., Plattner, R., Wang, Y.-L., **Wang, S.-C.** The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer. *Oncogene* 33, 1429-1437, 2014.
7. Lo, Y.-H., Ho, P.-C., Chen, M.-S., Hugo, E., Ben-Jonathan, N., **Wang, S.-C.** Phosphorylation at tyrosine 114 of Proliferating Cell Nuclear Antigen (PCNA) is required for adipogenesis in response to high fat diet. *Biochem. Biophys. Res. Commun.* 430, 43-48, 2013.
8. Yu, Y.-L., Chou, R.-H., Liang, J.-H., Chang, W.-J., Su, K. -J., Tseng, Y.- J., Huang, W.-C., **Wang, S.-C.**, Hung, M.-C. Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-Negative Breast Cancer Cells with Cell-Penetrating PCNA Peptides. *PLoS ONE* 8(4): e61362, 2013.
9. Cui, J., Germer, K., Wu, T., Wang, J., Luo, J., **Wang, S.-C.**, Wang, Q., Zhang, X. Crosstalk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells. *Cancer Research* 72, 5625-5634, 2012.

10. Hsieh, T.H., Tsai, C.-F., Hsu, C.-Y., Kuo, P.-L., His, E., Suen, J.-L., Hung, C.-H., Lee, J.-N., Chai, C.-Y., **Wang, S.-C.**, Tsai, E.-M. n-Butyl benzyl phthalate promotes breast cancer progression by inducing expression of lymphoid enhancer factor 1. *PLoS ONE* 7:e42750, 2012.
11. Lo, Y.-H., Ho, P.-C., **Wang, S.-C.** Epidermal growth factor receptor (EGFR) protects proliferating cell nuclear antigen (PCNA) from cullin 4a (CUL4A)-mediated proteolysis. *Journal of Biological Chemistry* 287, 27148-27157, 2012.
12. Zhao, H., Lo, Y.-H., Ho, P.-H., Bedford, M.T., Hung, M.-C., and **Wang, S.-C.*** Interaction of proliferation cell nuclear antigen (PCNA) with the non-receptor tyrosine kinase c-Abl in cell proliferation and response to DNA damages in breast cancer cells. *PLoS ONE* 7(1): e29416.
13. Hsieh, T.-H., Tsai, C.-F., Hsu, C.-Y., Kuo, P.-L., Lee, J.-N., Chai, C.-Y., **Wang, S.-C***, Tsai, E.-M.* Phthalates induce proliferation and invasiveness of estrogen receptor-negative breast cancer through the AhR/HDAC6/c-Myc signaling pathway. (*, co-corresponding authors) *Journal of the Federation of American Societies for Experimental Biology (FASEB J)* 26:778-787, 2012.
14. Ding, Q, Chang, C.-J., Xie, X., Xia, W., Yang, J.-Y., **Wang, S.-C.**, Wang, Y., Xia, J., Chen, L., Cai, C., Li, H., Yen, C.-J., Kuo, H.-P., Lee, D.-F., Lang, J., Huo, L., Cheng, X., Chen, Y.-J., Li, C.-W., Jeng, L.-B., Hsu, J.-L., Li, L.-Y., Tan, A., Curley, S.A., Ellis, L.M., DuBois, R.N., Hung, M.-C. APOBEC3G promotes liver metastasis in orthotopic colorectal cancer mouse model and predicts human hepatic metastasis. *Journal of Clinical Investigation* 121:4526-4536, 2011.
15. Lo, Y.-H., Ho, P.-C., Zhao, H., and **Wang, S.-C.** Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016). *Anticancer Research* 31:789-795, 2011.
16. Zhao, H., Lo, Y.-H., Ma, L., Waltz, S.E., Gray, J.K., Hung, M.-C., **Wang, S.-C.** Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth. *Molecular Cancer Therapeutics* 10:29-36, 2011.
17. Zhao, H., Lo, Y.-H., Yu, L. and **Wang, S.-C.** Overcoming resistance to fulvestrant (ICI182,780) by downregulating the c-ABL proto-Oncogene in breast cancer. *Molecular Carcinogenesis* 50:383-389, 2011.
18. Zhao, H., Ou-Yang, F., Chen, I.-F., Hou, M.-F., Yuan, S.-S. F., Chang, H.-L., Lee, Y.-C., Plattner, R., Waltz, S., Ho, S.-M., Sims, J., and **Wang, S.-C.** Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer. *Neoplasia* 12:214-223, 2010.

19. **Wang, S.-C.** and Hung, M.-C. Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. *Clinical Cancer Research* 15: 6484-6489, 2009.
20. Nakagawa-Goto, K., Yamada, K., Nakamura, K., Chen, T.-H., Chiang, P.-C., Bastow, K. F., **Wang, S.-C.**, Spohn, B., Hung, M.-C., Lee, F.-Y., Lee F.-C., and Lee, K.-H.. Antitumor agents. 258. Syntheses and evaluation of dietary antioxidant - taxoid conjugates as novel cytotoxic agents. *Bioorganic & Medicinal Chemistry Letters* 17:5204-5209, 2007.
21. **Wang, S.-C.**, Nakajima, Y., Yu, Y.-L., Xia, W., Chen, C.-T., Li, L.-Y., Hawke, D. H., Kobayashi, R., Hung, M.-C. Tyrosine phosphorylation controls PCNA function through protein stability. *Nature Cell Biology* 8:1359-1368, 2006.
22. Yu, Z, Xia, W., Wang, H., **Wang, S.-C.**, Pan, Y., Kwong, K.Y., Hortobagyi, G.N. And Hung, M-C. Antitumor activity on an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1. *Molecular Carcinogenesis* 45:667-675, 2006.
23. Xia, W.[‡], Lien, H.-C.[‡], **Wang, S.-C.**[‡], Pan, Y., Sahin, A., Kuo, Y.-H., Chang, K.-J., Zhou, X., Wang, H., Yu, Z., Hortobagyi, G., Shi, D.-R., and Hung, M.-C. ([‡], equally contributed) Expression of PEA3 and Lack of Correlation between PEA3 and HER-2/*neu* Expression in Breast Cancer. *Breast Cancer Research and Treatment* 98:295-301, 2006.
24. Chen, I-F., Ou-Yang, F., Hung, J-Y., Liu, J-C., Wang, H., **Wang, S-C.**, Hou, M-F., Hortobagyi, G.N. and Hung, M-C. AIM2 suppresses human breast cancer cell proliferation in vitro and mammary tumor growth in a mouse model. *Molecular Cancer Therapeutics* 5: 1-7, 2006.
25. **Wang, S.-C.** and Hung, M.-C. Cytoplasmic/nuclear shuttling and tumor progression. *Annals of the New York Academy of Sciences* 1059:1-5, 2005.
26. Giri, DK., Ali-Seyed, M., Li, L-Y., Lee, D-F., Ling, P., Bartholomeusz, G., **Wang, S.-C.** and Hung, M-C. Endosomal transport of ErbB-2: a mechanism for nuclear entry of cell surface receptor. *Molecular and Cellular Biology* 25:11005-11018, 2005.
27. **Wang, S.-C.** and Hung, M.-C. Finding the bEST routes to cancer. *Cancer Biology & Therapy* 3(11):e132-e133, 2004.
28. **Wang, S.-C.**, Lien, H.-C., Xia, W., Chen, I.-F., Lo, H.-W., Wang, Z., Ali-Seyed, M., Bartholomeusz, G., Ou-Yang, F., Giri, D.K., Hung, M.-C. Binding at and transactivation of the *COX-2* promoter by nuclear tyrosine kinase receptor ErbB-2. *Cancer Cell* 6, 251-261, 2004.

29. Makino, K., Day, C.-P., **Wang, S.-C.**, Li, Y.M., Hung, M.-C. Upregulation of IKK α /IKK β by integrin-linked kinase is required for HER2/neu-induced NF- κ B antiapoptotic pathway. *Oncogene* 23:3883-3887, 2004.
30. Lee, C.M., Lo, H.-W., Shao, R.-P., **Wang, S.-C.**, Xia, W., Gershenson, D.M., Hung, M.-C. Selective activation of ceruloplasmin promoter in ovarian tumors: potential use for gene therapy. *Cancer Research* 64:1788-1793, 2004.
31. Yan, D.H., Wen, Y., Su, L.K., Xia, W., **Wang, S.C.**, Zhang, S., Gan, L., Lee, D.-F., Spohn B., Frey, J.A., Hortobagyi, G.N., Hung, M.C. A delayed chemically-induced tumorigenesis in *Brca2* mutant mice. *Oncogene* 23:1896-1901, 2004.
32. Lee, C.M., Shvartsman, H., Deavers, M.T., **Wang, S.-C.**, Xia, W., Schmandt, R., Bodurka, D. C., Atkinson, E.N., Malpica, A., Gershenson, D.M., Hung, M.-C., Lu, K.H. β -catenin nuclear localization is associated with grade in ovarian serous carcinoma. *Gynecology Oncology* 88:363-368, 2003.
33. Asada, S., Choi, Y., Yamada, M., **Wang, S.-C.**, Hung, M.-C., Qin, J., Uesugi, M. External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. *Proceedings of the National Academy of Science USA (PNAS)* 99:12747-12752, 2002.
34. **Wang, S.-C.**, Shao, R., Pao, A.Y., Zhang, S., Hung, M.-C., and Su, L.-K. Inhibition of cancer cell growth by *BRCA2*. *Cancer Research* 62:1311-1314, 2002.
35. **Wang, S.-C.** and Hung, M.-C. HER2 over-expression and cancer targeting. *Seminars in Oncology* 28(5)(Suppl. 16):115-124, 2001.
36. **Wang, S.-C.**, Zhang, L., Hortobagyi, G.N. and Hung, M.-C. Targeting *HER-2*: Recent developments and future directions for breast cancer patients. *Seminars in Oncology* 28(6) (Suppl. 18):21-29, 2001.
37. Zou, Y., Peng, H., Zhou, B., Wen, Y., Tsai, E.-M., **Wang, S.-C.**, and Hung M.-C. Systemic tumor suppression by the pro-apoptotic gene *bik* *Cancer Research* 62:8-12, 2001.
38. **Wang, S.-C.**, Makino, K., Su, L.-K., Pao, A.Y., Kim, J.S., Hung, M.-C. Ultraviolet irradiation induces BRCA2 protein depletion through a p53-independent and protein synthesis-dependent pathway. *Cancer Research* 61:2838-2842, 2001.

39. Tsai, E.-M.[‡], **Wang, S.-C.**[‡], Hung, M.-C. ([‡], equally contributed) Akt activation by estrogen in estrogen receptor-negative breast cancer cells. *Cancer Research* 61:8390-8392, 2001. (impact factor 8.650)
40. **Wang, S.-C.**, Makino, K., Xia, W., Kim, J.S., Im, S.-A., Peng, H., Mok, S.C., Singletary, S.E., Hung, M.-C. DOC-2/hDab-2 inhibits ILK activity and induces anoikis in breast cancer cells through an Akt-independent pathway. *Oncogene* 20:6960-6964, 2001.
41. Hung, M.-C. and **Wang, S.-C.** Suppressing HER-2/*neu*-mediated cell trans-formation by transcriptional repressors. *Breast Disease* 11:133-144, 2000.
42. **Wang, S.-C.** and Hung, M.-C. Transcriptional targeting of the HER-2/*neu* oncogene. *Drugs of Today* 36(12):835-843, 2000.
43. Xing, X.[‡], **Wang, S.-C.**[‡], Xia, W., Zou, Y., Shao, R., Kwong, K.-Y., Yu, Z., Zhang, S., Miller, S., Huang, L., Hung, M.-C. ([‡], equally contributed) The Ets protein PEA3 suppresses HER-2/*neu* overexpression and inhibits tumorigenesis. *Nature Medicine* 6:189-195, 2000.
44. Lo, S.-S., Lo, S.-H., **Wang, S.-C.**, Hung, M.-C. Inhibition of focal contact formation in cells transformed by p185^{*neu*}. *Molecular Carcinogenesis* 25:150-154, 1999.
45. Su, L.-K., **Wang, S.-C.**, Qi, Y., Luo, W., Hung, M.-C., Lin, S.-H. Characterization of BRCA2: temperature sensitivity of detection and cell-cycle regulated expression. *Oncogene* 17:2377-2381, 1998.
46. **Wang, S.-C.**, Lin, S.-H., Su, L.-K., Hung, M.-C. Changes in BRCA2 expression during progression of the cell cycle. *Biochem. Biophys. Res. Commun.*, 234:247-251, 1997.